Prelude Therapeutics (PRLD) Q2 2024 Earnings
PRLD·Reported August 12, 2024·Before market open
Diluted EPS came in at $-0.46.
Diluted EPS
$-0.46met estimate
Consensus: $-0.46
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Prelude Therapeutics's Q2 2024 earnings report.
Prelude Therapeutics (PRLD) reported Q2 2024 earnings on August 12, 2024 before market open.
Prelude Therapeutics reported diluted EPS of $-0.46 for Q2 2024.
EPS beat the consensus estimate of $-0.46 by $0.00.
You can read the 10-Q periodic report (0000950170-24-095065) directly on SEC EDGAR. The filing index links above go to sec.gov.